Cancer-related pain (supportive care)
Also known as: Cancer pain, Oncological pain, Malignancy-associated pain, Tumour-related pain, Cancer treatment-related pain
Cancer-related pain may arise from tumour involvement, treatment-related tissue injury, or neuropathy, requiring assessment of its cause and functional impact. Oncology and palliative-care management, including prescribed analgesia, remains central. Comparative review data between oxycodone and alternative opioids report generally similar analgesia, with low or very low certainty for key comparisons [1]. An observational chemotherapy study documents substantial pain, constipation, fatigue, and appetite burden but does not test treatment efficacy [2]. Neither cited study evaluates acupuncture or Chinese herbal medicine. TCM patterns provide traditional frameworks for individualised supportive assessment, not explanations of cancer biology or evidence of benefit. Adjunctive interventions require oncology coordination and must not delay investigation or conventional treatment.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Maintain a daily record of average and worst pain, sleep, activity, and breakthrough analgesia use to share with the treating team.
- •Adhere to prescribed analgesic and bowel-care regimens; report troublesome sedation, constipation, or inadequate pain relief rather than adjusting medications independently.
- •Prioritise comfortable positioning and gentle activity approved for skeletal stability, falls risk, and current treatment effects.
- •Maintain tolerable nutrition, mouth care, and regular rest; access dietetic, psychological, or palliative-care support when needed.
Cautions & Contraindications
- •Do not replace or independently reduce prescribed analgesia with acupuncture or herbs. Review sedation, constipation and other adverse effects with the prescriber; the opioid review provides comparative drug evidence, not a withdrawal protocol.[]
- •Defer needling in acute illness, uncontrolled bleeding, or clinically significant neutropenia or thrombocytopenia until oncology clearance. Review current blood counts and local service policy; the supplied chemotherapy study does not define safe needling thresholds.[]
- •Do not needle through tumours, infected or damaged skin, radiotherapy injury, ports, lines or recent surgical sites. Avoid affected lymphoedematous limbs and unsafe areas over bone lesions; these are clinical precautions, not findings tested in the supplied abstracts.[]
- •Do not start herbal products during anticancer treatment without oncology-pharmacist review of interactions, bleeding risk and organ function. Neither supplied abstract establishes herbal safety or efficacy.[,]
When to reassess or seek care again
Record baseline average and worst pain on a 0–10 scale, pain interference, sleep, bowel function, breakthrough analgesic use and adverse effects. Review tolerability after each session and overall outcomes within 1–2 weeks or after 2–3 sessions. Agree a meaningful functional goal with the patient. Stop or modify adjunctive care if there is no useful improvement, increased burden or adverse effects. Escalating pain, increasing rescue-medicine requirements or new symptoms require prompt prescriber review; red flags require immediate escalation rather than waiting for review.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- The Cochrane database of systematic reviews · 2017
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
